FDA approves Alcon's Simbrinza for glaucoma and ocular hypertension

04/22/2013 | RTT News

Novartis unit Alcon obtained approval from the FDA to market Simbrinza Suspension, a fixed-dose combination of Brinzolamide and Brimonidine Tartrate, for the reduction of elevated intraocular pressure in patients suffering from primary open-angle glaucoma or ocular hypertension. The approval makes Simbrinza the first fixed-dose glaucoma combo treatment in the U.S. that doesn't contain a beta blocker.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA